Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus

Stopped The trial was terminated prematurely as it met pre-defined criteria for futility at IA3.

Conditions

• Active Systemic Lupus Erythematosus

Interventions

• DRUG: Efavaleukin Alfa
• DRUG: Placebo
• OTHER: Standard of Care

Sponsor

Amgen